drugset / Trial / NCT05284097
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
Phase 2
Completed
133 enrolled
London School of Hygiene and Tropical Medicine
Janssen Vaccines & Prevention B.V. · collabUniversity of Sierra Leone · collab
NaSingle-groupOpen-labelPrevention
Summary
This is a Phase 2, open-label, study evaluating the safety and immunogenicity of the 2-dose vaccination regimen, Ad26.ZEBOV, MVA-BN-Filo, in adults and children originally enrolled in the control arm of the EBOVAC-Salone study
Timeline
- Start
- 2022-09-19
- Primary completion
- 2023-03-02
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN | Vaccine | 5e+10 vg | Intramuscular |
| Subject | MVA-BN-Filo | Vaccine | 1e+08 unknown | Intramuscular |